Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 6, 1999

View Archived Issues

Ganciclovir may reduce atherosclerosis in transplant patients

Combination immunotherapy kills melanoma in mice

Vical: Q2 1999 highlights

Viron Therapeutics awarded US patent for use of viral proteins as antiinflammatory agents

Pharmacia & Upjohn provides update on Q2 1999 progress

Bristol-Myers Squibb and ICAgen extend cardiovascular collaboration

Women First to market Fournier's estradiol patch in U.S.

Vaccination with HPV16 peptides in advanced cervical carcinoma

Liposome initiates clinical trial of Evacet in combination with Herceptin

Discovery Laboratories begins phase II tyloxapol trial in cystic fibrosis

MacroChem reports results of safety trials with Topiglan

Health Canada approves Integrilin for marketing

Vitravene approved in E.U. for CMV retinitis

Jenner Biotherapies receives patent protection for JBT-3002, a novel macrophage activator

GenVec gene therapy shows promising phase I results in patients with severe coronary artery disease

Dual 5-HT2/alpha1-adrenoceptor antagonists for treating cardiovascular disorders

Novel dual cephem-oxazolidinones described by Korean researchers

Novel cell adhesion inhibitors prepared by Rhone-Poulenc Rorer

Anti-H. pylori agents isolated from natural source by Takeda team

Hokuriku Seiyaku's STAT5 activators are useful for regulating platelet production

Teijin prepares factor Xa inhibitor series

ADIR discloses alkaloid derivatives with improved potency and solubility

FDA approves injectable, oral formulations of Wyeth-Ayerst's Protonix

Another pharmaceutical industry merger in the making: Cypros and RiboGene

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...